

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 May–June 2021

Morbidity and Mortality Weekly Report
70, 1081-1083

DOI: [10.15585/mmwr.mm7032e1](https://doi.org/10.15585/mmwr.mm7032e1)

Citation Report

#	ARTICLE	IF	CITATIONS
6	Vaccinating people who have had covid-19: why doesn't natural immunity count in the US?. <i>BMJ</i> , The, 2021, 374, n2101.	3.0	28
7	Towards AI-Enabled Multimodal Diagnostics and Management of COVID-19 and Comorbidities in Resource-Limited Settings. <i>Informatics</i> , 2021, 8, 63.	2.4	11
8	Natural vs. Vaccine Mediated COVID-19 Immunity Scientific Justification to Mandate Vaccination of Recovered Healthcare Workers. <i>DHR Proceedings</i> , 2021, 1, 15-16.	0.8	0
9	Results of Serosurveillance and Forecasting the Third Wave of COVID-19 in an Industrial District in India. <i>Cureus</i> , 2021, 13, e18097.	0.2	0
11	A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection. Evaluation and the Health Professions, 2021, 44, 327-332.	0.9	79
12	Return to School and COVID-19 Vaccination for Pediatric Solid Organ Transplant Recipients in the United States: Expert Opinion for 2021-2022. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 43-54.	0.6	7
13	The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome. <i>Interface Focus</i> , 2021, 11, 20210008.	1.5	24
15	SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11001.	1.2	14
16	COVID reinfections likely within one or two years, models propose. <i>Nature</i> , 2021, , .	13.7	3
17	Equivalency of Protection From Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic Review and Pooled Analysis. <i>Cureus</i> , 2021, 13, e19102.	0.2	50
18	Reinfection and Breakthrough Infection of SARS-CoV-2: An Emerging Challenge That Is Threatening Our World. <i>Infectious Diseases & Immunity</i> , 2022, 2, 29-33.	0.2	3
20	Multistate Outbreak of SARS-CoV-2 Infections, Including Vaccine Breakthrough Infections, Associated with Large Public Gatherings, United States. <i>Emerging Infectious Diseases</i> , 2022, 28, 36-44.	2.0	19
21	Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. <i>Lancet Microbe</i> , The, 2022, 3, e52-e61.	3.4	436
22	Spatial Analysis of COVID-19 Vaccination: A Scoping Review. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12024.	1.2	18
23	Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection Associates With Unstable Housing and Occurs in the Presence of Antibodies. <i>Clinical Infectious Diseases</i> , 2022, 75, e208-e215.	2.9	16
24	COVID-19 Delta Variant: Perceptions, Worries, and Vaccine-Booster Acceptability among Healthcare Workers. <i>Healthcare (Switzerland)</i> , 2021, 9, 1566.	1.0	57
26	Management of post-acute COVID-19 patients in geriatric rehabilitation: EuGMS guidance. <i>European Geriatric Medicine</i> , 2022, 13, 291-304.	1.2	16
27	Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. <i>Translational Research</i> , 2022, 241, 1-12.	2.2	15

#	ARTICLE	IF	CITATIONS
28	Covid-19 Vaccine Effectiveness in New York State. <i>New England Journal of Medicine</i> , 2022, 386, 116-127.	13.9	233
30	Evaluation of two rapid lateral flow tests and two surrogate ELISAs for the detection of SARS-CoV-2 specific neutralizing antibodies. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
31	Detection of significant antiviral drug effects on COVID-19 using viral load and PCR-positive rate in randomized controlled trials. <i>Translational and Regulatory Sciences</i> , 2021, 3, 85-88.	0.2	0
33	Public Perceptions of Current COVID-19 Vaccinations. Results of a Pilot Survey. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110669.	0.7	4
34	Risk for Reinfection After SARS-CoV-2: A Living, Rapid Review for American College of Physicians Practice Points on the Role of the Antibody Response in Conferring Immunity Following SARS-CoV-2 Infection. <i>Annals of Internal Medicine</i> , 2022, 175, 547-555.	2.0	38
35	SARS-CoV-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
36	Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2. <i>Journal of Translational Medicine</i> , 2022, 20, 22.	1.8	11
37	Necessity of Coronavirus Disease 2019 (COVID-19) Vaccination in Persons Who Have Already Had COVID-19. <i>Clinical Infectious Diseases</i> , 2022, 75, e662-e671.	2.9	59
38	SARS-CoV-2 Variants, Vaccines, and Host Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 809244.	2.2	176
39	SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India. <i>JAMA Network Open</i> , 2022, 5, e2142210.	2.8	48
40	What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 2). <i>Annals of Internal Medicine</i> , 2022, , .	2.0	1
41	COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis – California and New York, May–November 2021. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 125-131.	9.0	119
42	Vaccine Effectiveness Against COVID-19 Infection and Onward Transmission by Variant of Concern and Time Since Vaccination, Belgian Contact Tracing, 2021. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
43	Persistence of Anti-SARS-CoV-2 Antibodies in Long Term Care Residents Over Seven Months After Two COVID-19 Outbreaks. <i>Frontiers in Immunology</i> , 2021, 12, 775420.	2.2	8
44	Effect of vaccination on SARS-CoV-2 reinfection risk: a case-control study in the Republic of Cyprus. <i>Public Health</i> , 2022, 204, 84-86.	1.4	1
45	Identifying and Alleviating Bias Due to Differential Depletion of Susceptible People in Postmarketing Evaluations of COVID-19 Vaccines. <i>American Journal of Epidemiology</i> , 2022, 191, 800-811.	1.6	53
46	Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. <i>Science Immunology</i> , 2022, 7, eabn8014.	5.6	220
47	Sexual dimorphism in COVID-19: potential clinical and public health implications. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 221-230.	5.5	78

#	ARTICLE	IF	CITATIONS
48	Post-COVID-19 vaccination adverse events and healthcare utilization among individuals with or without previous SARS-CoV-2 infection. <i>Journal of Internal Medicine</i> , 2022, 291, 864-869.	2.7	21
49	Cost-effective proactive testing strategies during COVID-19 mass vaccination: A modelling study. <i>The Lancet Regional Health Americas</i> , 2022, 8, 100182.	1.5	10
50	Modelling epidemic spreading in structured organisations. <i>Physica A: Statistical Mechanics and Its Applications</i> , 2022, 592, 126875.	1.2	5
51	Study on the Refusal of Vaccination against COVID-19 in Romania. <i>Vaccines</i> , 2022, 10, 261.	2.1	22
52	Cellular Responses to Membrane and Nucleocapsid Viral Proteins Are Also Boosted After SARS-CoV-2 Spike mRNA Vaccination in Individuals With Either Past Infection or Cross-Reactivity. <i>Frontiers in Microbiology</i> , 2021, 12, 812729.	1.5	5
53	Evaluation of Two Rapid Lateral Flow Tests and Two Surrogate ELISAs for the Detection of SARS-CoV-2 Specific Neutralizing Antibodies. <i>Frontiers in Medicine</i> , 2022, 9, 820151.	1.2	11
54	Post-Vaccination SARS-CoV-2 Infections among Health Workers at the University Hospital of Verona, Italy: A Retrospective Cohort Survey. <i>Vaccines</i> , 2022, 10, 272.	2.1	24
56	SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. <i>Environmental Research</i> , 2022, 209, 112911.	3.7	181
58	SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History. <i>Microbiology Spectrum</i> , 2022, 10, e0226221.	1.2	5
59	An Opportunity to Understand Concerns about COVID-19 Vaccination: Perspectives from EMS Professionals. <i>Vaccines</i> , 2022, 10, 380.	2.1	3
60	Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. <i>New England Journal of Medicine</i> , 2022, 386, 1207-1220.	13.9	452
61	SARS-CoV-2 and Influenza A Virus Coinfections in Ferrets. <i>Journal of Virology</i> , 2022, 96, JVI0179121.	1.5	23
62	Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity. <i>Frontiers in Immunology</i> , 2022, 13, 830433.	2.2	12
63	Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2022, 226, 1224-1230.	1.9	13
64	Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19. <i>New England Journal of Medicine</i> , 2022, 386, 1221-1229.	13.9	98
65	Outcomes After SARS-CoV-2 Vaccination Among Children With a History of Multisystem Inflammatory Syndrome. <i>JAMA Network Open</i> , 2022, 5, e224750.	2.8	7
66	Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases. <i>RNA Biology</i> , 2022, 19, 386-410.	1.5	19
67	Reinfection in COVID-19: Do we exaggerate our worries?. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13767.	1.7	11

#	ARTICLE	IF	CITATIONS
69	Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID. <i>Journal of Medical Virology</i> , 2022, 94, 3416-3420.	2.5	41
70	It is not too late to achieve global covid-19 vaccine equity. <i>BMJ, The</i> , 2022, 376, e070650.	3.0	62
71	Low Levels of Neutralizing Antibodies After Natural Infection With Severe Acute Respiratory Syndrome Coronavirus 2 in a Community-Based Serological Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac055.	0.4	4
72	Postâ€“COVID-19 syndrome and humoral response association after 1Â year in vaccinated and unvaccinated patients. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1140-1148.	2.8	35
73	Couples and COVID-19 vaccination: Frequency and reasons for discordance. <i>Vaccine</i> , 2022, 40, 1913-1917.	1.7	3
75	A Clinicianâ€™s Obligation to be Vaccinated: Four Arguments that Establish a Duty for Healthcare Professionals to be Vaccinated Against COVID-19. <i>Journal of Bioethical Inquiry</i> , 2022, 19, 451-465.	0.9	5
76	Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. <i>Lancet Infectious Diseases, The</i> , 2022, 22, 791-801.	4.6	84
77	Vaccination and natural immunity: Advantages and risks as a matter of public health policy. <i>The Lancet Regional Health Americas</i> , 2022, 8, 100242.	1.5	1
78	<i>Notes from the Field: </i>SARS-CoV-2 Omicron Variant Infection in 10 Persons Within 90 Days of Previous SARS-CoV-2 Delta Variant Infection â€” Four States, October 2021â€“January 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 524-526.	9.0	8
79	Cellular Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination Schemes Authorized by the Chilean Ministry of Health in January 2022. <i>Life</i> , 2022, 12, 534.	1.1	3
80	Hybrid immunity against COVID-19 in different countries with a special emphasis on the Indian scenario during the Omicron period. <i>International Immunopharmacology</i> , 2022, 108, 108766.	1.7	12
83	Coronavirus Disease 2019 (COVID-19) Vaccination for Children: Position Statement of Indian Academy of Pediatrics Advisory Committee on Vaccination and Immunization Practices. <i>Indian Pediatrics</i> , 2022, 59, 51-57.	0.2	10
84	The Effectiveness of Post-Vaccination and Post-Infection Protection in the Hospital Staff of Three Prague Hospitals: A Cohort Study of 8-Month Follow-Up from the Start of the COVID-19 Vaccination Campaign (COVANESS). <i>Vaccines</i> , 2022, 10, 9.	2.1	11
85	A 48-Year-Old Immunocompetent Female Resident of Southern Florida with Confirmed Reinfection with P.1 (Gamma) Variant of SARS-CoV-2. <i>American Journal of Case Reports</i> , 2022, 23, e935329.	0.3	0
87	Vaccine-induced immune responses against SARS-CoV-2 infections. <i>Exploration of Immunology</i> , 0, , 356-373.	1.7	0
88	An update on host immunity correlates and prospects of re-infection in COVID-19. <i>International Reviews of Immunology</i> , 2022, 41, 367-392.	1.5	9
91	Vaccination and Covid 19 Infections. <i>Medicina Interna (Bucharest, Romania: 1991)</i> , 2022, 19, 97-105.	0.1	0
92	Persistence of SARS-CoV-2 Antibodies in Vaccinated Health Care Workers Analyzed by Coronavirus Antigen Microarray. <i>Frontiers in Immunology</i> , 2022, 13, 817345.	2.2	5

#	ARTICLE	IF	CITATIONS
94	Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium. <i>Viruses</i> , 2022, 14, 802.	1.5	30
95	Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021. <i>Vaccine</i> , 2022, 40, 3027-3037.	1.7	18
96	Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel. <i>Nature Communications</i> , 2022, 13, 2202.	5.8	13
97	Barriers to COVID-19 Vaccines and Strategies to Improve Acceptability and Uptake. <i>Journal of Pharmacy Practice</i> , 2023, 36, 900-904.	0.5	12
98	Coronavirus Disease 2019 (COVID-19) Vaccination for Children: Position Statement of Indian Academy of Pediatrics Advisory Committee on Vaccination and Immunization Practices.. <i>Indian Pediatrics</i> , 2021, , .	0.2	2
99	Making waves: Wastewater surveillance of SARS-CoV-2 in an endemic future. <i>Water Research</i> , 2022, 219, 118535.	5.3	37
100	Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection. <i>BMC Medicine</i> , 2022, 20, 181.	2.3	10
101	COVID-19 Booster Vaccination Hesitancy in the United States: A Multi-Theory-Model (MTM)-Based National Assessment. <i>Vaccines</i> , 2022, 10, 758.	2.1	24
102	Enhancing resilience in construction against infectious diseases using stochastic multi-agent approach. <i>Automation in Construction</i> , 2022, 140, 104315.	4.8	5
103	The Primacy of Moringa (<i>Moringa oleifera</i> Lam.) in Boosting Nutrition Status and Immunity Defence Amidst the COVID-19 Catastrophe: A Perspective. <i>Phyton</i> , 2022, 91, 1831-1858.	0.4	1
104	Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. <i>Clinical Infectious Diseases</i> , 2023, 76, e439-e449.	2.9	23
105	Trajectory patterns of SARS-CoV-2 neutralising antibody response in convalescent COVID-19 patients. <i>Communications Medicine</i> , 2022, 2, .	1.9	2
106	Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review. , 2022, 10, 251513552210975.	1.4	6
108	Clinical Characteristics and Outcomes of Patients With SARS-CoV-2 Reinfection. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2022, 6, 361-372.	1.2	4
109	Vaccination against the new coronavirus infection SARS-CoV-2. The current state of the problem. <i>Russian Pediatric Journal</i> , 2022, 25, 139-146.	0.0	0
110	A Primer on <sc>Postâ€œCOVID</sc> â€œ19 Conditions and Implications for Clinical Pharmacists. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 0, , .	0.5	0
111	Association of Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination or a Prior Positive Test Result in Adolescents during the Delta Variant Surge in Kentucky. <i>Journal of Pediatrics</i> , 2022, 248, 119-121.	0.9	3
112	Are we suffering from the Peltzman effect? Risk perception among recovered and vaccinated people during the COVID-19 pandemic in Israel. <i>Public Health</i> , 2022, 209, 19-22.	1.4	7

#	ARTICLE	IF	CITATIONS
114	Reduced Odds of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Vaccination Among New York City Adults, July 2021–November 2021. <i>Clinical Infectious Diseases</i> , 2023, 76, e469-e476.	2.9	9
115	Public Perception of SARS-CoV-2 Vaccines Among Psoriasis Patients in Social Media: Content, Sentiment, and Engagement Analysis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 0, , 247553032211100.	0.3	0
116	Addressing COVID-19 vaccine hesitancy. <i>Drugs in Context</i> , 0, 11, 1-19.	1.0	11
117	Booster Vaccination Decreases 28-Day All-Cause Mortality of the Elderly Hospitalized Due to SARS-CoV-2 Delta Variant. <i>Vaccines</i> , 2022, 10, 986.	2.1	7
118	SARS-CoV-2 variants and the global pandemic challenged by vaccine uptake during the emergence of the Delta variant: A national survey seeking vaccine hesitancy causes. <i>Journal of Infection and Public Health</i> , 2022, 15, 773-780.	1.9	11
119	Horny for COVID. <i>Extrapolation</i> , 2022, 63, 55-73.	0.1	0
120	Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals. <i>PLoS ONE</i> , 2022, 17, e0264298.	1.1	0
121	Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia. <i>PLoS ONE</i> , 2022, 17, e0270801.	1.1	18
122	Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA. <i>Lancet, The</i> , 2022, 400, 535-538.	6.3	27
123	Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	6
124	Quantifying the immunological distinctiveness of emerging SARS-CoV-2 variants in the context of prior regional herd exposure. , 0, , .		0
125	A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. <i>Pharmaceutical Research</i> , 2022, 39, 2119-2134.	1.7	10
126	SARS-CoV-2 Antibody Response against Mild-to-Moderate Breakthrough COVID-19 in Home Isolation Setting in Thailand. <i>Vaccines</i> , 2022, 10, 1131.	2.1	3
127	<scp>COVID</scp>â€19 and plasma cells: Is there longâ€lived protection?*. <i>Immunological Reviews</i> , 2022, 309, 40-63.	2.8	26
128	Two cases of acute respiratory failure following <scp>SARSâ€CoV</scp> â€2 vaccination in postâ€• <scp>COVID</scp> â€19 pneumonia. <i>Respirology Case Reports</i> , 2022, 10, .	0.3	2
129	Risk and severity of SARS-CoV-2 reinfections during 2020â€2022 in Vojvodina, Serbia: A population-level observational study. <i>Lancet Regional Health - Europe, The</i> , 2022, 20, 100453.	3.0	47
130	Protection Against the Omicron Variant Offered by Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2023, 76, e142-e147.	2.9	8
131	Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection. <i>JAMA Network Open</i> , 2022, 5, e2223917.	2.8	19

#	ARTICLE	IF	CITATIONS
132	Reinfection with SARS-CoV-2 in general population, South Korea; nationwide retrospective cohort study. <i>Journal of Medical Virology</i> , 2022, 94, 5589-5592.	2.5	15
133	Estimating COVID-19 Vaccination and Booster Effectiveness Using Electronic Health Records From an Academic Medical Center in Michigan. , 2022, 1, 100015.		1
134	Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria. <i>Viruses</i> , 2022, 14, 1642.	1.5	4
135	High SARS-CoV-2 Seroprevalence and Rapid Neutralizing Antibody Decline among Agricultural Workers in Rural Guatemala, June 2020–March 2021. <i>Vaccines</i> , 2022, 10, 1160.	2.1	1
136	Mild reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant: First case report from Indonesia. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
137	Effects of vaccination, new SARS-CoV-2 variants and reinfections on post-COVID-19 complications. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	5
138	The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	70
139	Development of robust, indigenous ELISA for detection of IgG antibodies against CoV-2-N and S proteins: mass screening. <i>Applied Microbiology and Biotechnology</i> , 0, , .	1.7	2
140	Rapid Increase in Suspected SARS-CoV-2 Reinfections, Clark County, Nevada, USA, December 2021. <i>Emerging Infectious Diseases</i> , 2022, 28, 1977-1981.	2.0	8
141	Epidemiological assessment of SARS-CoV-2 reinfection. <i>International Journal of Infectious Diseases</i> , 2022, 123, 9-16.	1.5	13
142	COVID-19 in patients with B cell immune deficiency. <i>Journal of Immunological Methods</i> , 2022, 510, 113351.	0.6	1
143	An assessment of COVID-19 infection after vaccination amongst health-care workers at a tertiary care centre, kodagu, Karnataka. <i>Journal of Medical Evidence</i> , 2022, .	0.2	0
144	Covid-19 vaccine hesitancy: Text mining, sentiment analysis and machine learning on COVID-19 vaccination Twitter dataset. <i>Expert Systems With Applications</i> , 2023, 212, 118715.	4.4	65
145	Microbiological and Clinical Findings of SARS-CoV-2 Infection after 2 Years of Pandemic: From Lung to Gut Microbiota. <i>Diagnostics</i> , 2022, 12, 2143.	1.3	4
146	Effectiveness of Booster Doses of the SARS-CoV-2 Inactivated Vaccine KCONVAC against the Mutant Strains. <i>Viruses</i> , 2022, 14, 2016.	1.5	8
148	Acceptance of coronavirus disease 2019 vaccination among postpartum women during delivery hospitalization. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 0, , 1-4.	0.7	0
149	Public knowledge and attitude towards COVID-19 vaccines, implementation of preventive measures following vaccination, and perceived stress during the COVID-19 pandemic: A cross-sectional study in Jordan. <i>Electronic Journal of General Medicine</i> , 2022, 19, em421.	0.3	1
150	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5

#	ARTICLE	IF	CITATIONS
151	COVID-19 Vaccination Intention and Factors Associated with Hesitance and Resistance in the Deep South: Montgomery, Alabama. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 331.	0.9	1
153	Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection. <i>MSphere</i> , 2022, 7, .	1.3	3
154	Likelihood of COVID-19 reinfection in an urban community cohort in Massachusetts. , 2022, 1, 100057.		0
155	Epidemiology and Clinical Presentation of COVID-19 in Older Adults. <i>Infectious Disease Clinics of North America</i> , 2023, 37, 1-26.	1.9	10
156	COVID-19 vaccines reduce the risk of SARS-CoV-2 reinfection and hospitalization: Meta-analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	16
157	SARS-CoV-2 neutralizing antibody response in vaccinated and non-vaccinated hospital healthcare workers with or without history of infection. <i>Microbes and Infection</i> , 2022, , 105077.	1.0	2
158	Smoking cessation in the elderly as a sign of susceptibility to symptomatic COVID-19 reinfection in the United States. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
159	Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. <i>PLoS Medicine</i> , 2022, 19, e1004037.	3.9	28
160	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. <i>Stem Cell Reviews and Reports</i> , 0, , .	1.7	2
161	Association of dual COVID-19 and seasonal influenza vaccination with COVID-19 infection and disease severity. <i>Vaccine</i> , 2023, 41, 875-878.	1.7	9
162	B-Cell Responses to Sars-Cov-2 mRNA Vaccines. <i>Pathogens and Immunity</i> , 2022, 7, 93-119.	1.4	0
163	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 600-638.	0.5	1
165	Antibody response to receptor-binding domain of SARS-CoV-2 spike protein following vaccination and natural infection with SARS-CoV-2. <i>IMC Journal of Medical Science</i> , 0, , 1-7.	0.4	0
166	Pfizer-BioNTech COVID-19 vaccine effectiveness against SARS-CoV-2 infection among long-term care facility staff with and without prior infection in New York City, Januaryâ€“June 2021. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	0
167	Current and Emerging Knowledge in COVID-19. <i>Radiology</i> , 2023, 306, .	3.6	30
168	COVID-19 Risk Compensation? Examining Vaccination Uptake among Recovered and Classification of Breakthrough Cases. <i>Healthcare (Switzerland)</i> , 2023, 11, 58.	1.0	2
169	Factors Associated with Intention to Vaccinate Children 0-11 Years of Age Against COVID-19. <i>Journal of the American Board of Family Medicine</i> , 2022, 35, 1174-1178.	0.8	1
171	Dynamics of Antibody Responses after Asymptomatic and Mild to Moderate SARS-CoV-2 Infections: Real-World Data in a Resource-Limited Country. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 185.	0.9	0

#	ARTICLE	IF	CITATIONS
172	Understanding the barriers and facilitators of vaccine hesitancy towards the COVID-19 vaccine in healthcare workers and healthcare students worldwide: An Umbrella Review. PLoS ONE, 2023, 18, e0280439.	1.1	11
173	Early Career Occupational Therapistsâ€™ Experiences during the COVID-19 Pandemic. Occupational Therapy in Health Care, 0, , 1-20.	0.2	1
174	COVID-19 Vaccination in Paediatric Population of India: Current Status, Trends, Challenges and Recommendations. Journal of Pure and Applied Microbiology, 2023, 17, 69-79.	0.3	0
175	SARS-CoV-2-Neutralizing Antibody Response and Correlation of Two Serological Assays with Microneutralization. Vaccines, 2023, 11, 590.	2.1	3
176	Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico. Frontiers in Public Health, 0, 11, .	1.3	7
186	Antibody titers of individuals vaccinated for COVID-19: A systematic review. Journal of Biosciences, 2023, 48, .	0.5	0